argenx SE reported $394M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AstraZeneca USD 7.11B 4.14B Mar/2026
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GRIFOLS EUR 249M 26.38M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Qiagen NV USD 121.88M 15.41M Dec/2025
UCB EUR 1.29B 571M Dec/2025